← Back to patent-cliff list
Ga-68 Dolacga
Tier C — Watch / tradeGa-68 Dolacga
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ASGPR
Indications (approved)：Hepatocellular carcinoma, Liver cancer
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ga-68 Dolacga?
Approved indications include: Hepatocellular carcinoma, Liver cancer.
When does the Ga-68 Dolacga patent expire?
No public expiry year is available for Ga-68 Dolacga yet; this page updates once verified.
How do I get a quote for Ga-68 Dolacga intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06